Bunte T, Hahmann H W, Hellwig N, Hau U, Becker D, Dyckmans J, Keller H E, Schieffer H J
Institut für Präventive Kardiologie, Universitätskliniken des Saarlandes, Homburg, Germany.
Atherosclerosis. 1993 Jan 25;98(2):127-38. doi: 10.1016/0021-9150(93)90123-c.
Within the framework of a prospective lipid-lowering intervention study 44 patients were treated over a period of 3 years with a lipid-lowering diet and 200-400 mg fenofibrate daily. The intervention led to statistically significant decreases in total cholesterol (Chol), low density lipoprotein cholesterol (LDL-Chol) and triglycerides levels, and to a significant increase in high density lipoprotein cholesterol (HDL-Chol) levels. Despite intervention, in 8 patients the HDL-Chol levels decreased by up to 20 mg/dl, where these were mainly patients with high initial values. Likewise, the triglycerides of 4 patients whose initial levels were relatively low increased (up to 49 mg/dl) and the LDL-Chol levels of 8 patients whose initial levels were also low increased (up to 49 mg/dl). Only minor success was achieved through the 6-week diet, but this was still slightly significant for Chol and LDL-Chol levels. A total of 21 patients underwent repeat angiography within 3 years for clinical reasons. For the evaluation of the angiographic progress a total of 98 minor and moderate stenoses was measured using digital image processing and automatic contour finding. The change in the angiographic parameters 'percent diameter reduction' (%DR) and 'percent plaque area' (%PA) correlated with on-treatment LDL-Chol levels (%DR change with LDL-Chol: r = 0.67, P = 0.0005; %DR change with Chol: r = 0.61, P = 0.002; %PA change with LDL-Chol: r = 0.40, P = 0.037; %PA change with Chol: r = 0.38, P = 0.044), while for HDL-Chol and triglycerides no influence on the angiographic progress could be demonstrated. On the basis of the reproducibility of the measuring methods the patients were classified in the categories 'regression', 'unchanged' and 'progression'. The patients classified as 'regression' (parameter: %DR change) showed an LDL-Chol mean value of 162 +/- 9 mg/dl, whereas those classified as 'unchanged' or 'progression' showed values of 189 +/- 25 mg/dl and 199 +/- 21 mg/dl, respectively (P = 0.014). A negative correlation appeared between the angiographic progress parameters and the initial degree of stenosis. The left ventricular ejection fraction in the second angiography showed relationships to lipoprotein levels and angiographic progress parameters.
在一项前瞻性降脂干预研究的框架内,44例患者接受了为期3年的降脂饮食治疗,并每日服用200 - 400毫克非诺贝特。干预导致总胆固醇(Chol)、低密度脂蛋白胆固醇(LDL - Chol)和甘油三酯水平在统计学上显著降低,高密度脂蛋白胆固醇(HDL - Chol)水平显著升高。尽管进行了干预,但仍有8例患者的HDL - Chol水平下降了多达20毫克/分升,这些患者主要是初始值较高的患者。同样,4例初始水平相对较低的患者甘油三酯升高(高达49毫克/分升),8例初始水平也较低的患者LDL - Chol水平升高(高达49毫克/分升)。为期6周的饮食干预仅取得了较小的成效,但对Chol和LDL - Chol水平仍有轻微的显著影响。共有21例患者因临床原因在3年内接受了重复血管造影。为了评估血管造影进展情况,使用数字图像处理和自动轮廓查找技术共测量了98处轻度和中度狭窄。血管造影参数“直径缩小百分比”(%DR)和“斑块面积百分比”(%PA)的变化与治疗期间的LDL - Chol水平相关(%DR变化与LDL - Chol:r = 0.67,P = 0.0005;%DR变化与Chol:r = 0.61,P = 0.002;%PA变化与LDL - Chol:r = 0.40,P = 0.037;%PA变化与Chol:r = 0.38,P = 0.044),而对于HDL - Chol和甘油三酯,未显示对血管造影进展有影响。基于测量方法的可重复性,将患者分为“消退”、“不变”和“进展”三类。分类为“消退”(参数:%DR变化)的患者LDL - Chol平均值为162±9毫克/分升,而分类为“不变”或“进展”的患者分别为189±25毫克/分升和199±21毫克/分升(P = 0.014)。血管造影进展参数与初始狭窄程度之间呈负相关。第二次血管造影时的左心室射血分数与脂蛋白水平和血管造影进展参数相关。